Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Just sayin. LC is right, I don’t know.
The last paragraph first: copy n paste:
“Merck has become dependent on Keytruda for more than 40% of company sales and faces a revenue hit when Keytruda’s main U.S. patent expires in 2028.”
12:29 PM EDT, April 25, 2024 (Benzinga Newswire)
On Thursday, US drug maker Merck & Co Inc (NYSE:MRK) reported first-quarter sales of $15.8 billion, up 9% year-over-year, beating the consensus estimate of $15.2 billion.
Excluding the impact of foreign exchange, sales increased 24%.
Merck reported adjusted EPS of $2.07, up 48%Y/Y, beating the consensus of $1.88.
Merck’s pharmaceutical unit booked $14.01 billion in revenue during the first quarter, up 10% Y/Y.
Related: Merck’s $11B Bet Pays As FDA Approves Sotatercept For Rare Lung Disease.
Merck’s blockbuster cancer immunotherapy Keytruda largely drove the growth. Keytruda generated $6.95 billion in revenue during the quarter, up 20% from the year-earlier period.
Merck has become dependent on Keytruda for more than 40% of company sales and faces a revenue hit when Keytruda’s main U.S. patent expires in 2028.”….
UK Sawston facility Advent will make the vaccines for the whole Europe I guess. Everywhere else specifically, USA, would be Franchise; does it make sense? Ask BMY. Looks like FW is a huge success.
Thank you Dstock.
Appreciate your reply.
It saddens my heart to hear a 13 old girl having such a terrible disease. The RA needs to cut the red tape and makes this treatment available the patients ASAP.
Thank you for sharing this. Will share this with my wife.
Yes I saw NCI and when I see NCI it’s nothing but good- they have something like 100 cancer treatment centers across the US.
However, Crystal Mackall is a hero-would be a nice addition to team nwbo.
Side story- working on the driver today with an instructor who I just learned his 13 YO daughter has a grade 3 brain cancer, a subset of GBM. She’s doing well after surgery and entering 2nd round of chemo mid May. Sweet young man that needs positive thought for his family and daughter- put in a good word for Mike and his family they need it and appreciated.
50:1 reverse split?
Also this RevImmune nonsense has been around forever. But I could see a crushing reverse merge where everything goes away with a fresh start.
"The mere thought of kicking someone when they're most vulnerable,"
help me out here, he sold NWBO to buy another stock, what about this situation for him is 'vulnerable'
this strikes me as nothing but another win for shorts trying to spook out weak hands...
Thanks for your kind words and your advice ilovetech!! Appreciate it
Thanks Brooktrail1933. Agree with you, now he is on ignore for me also. No reason to argue with somebody like that. Good luck to us all
tryn2 - I'll be honest, I've stewed on this manipulation thing for a long time. There's nothing worse than being robbed blind and powerless imo. This CUSIP option is absolutely fascinating to me for a couple of reasons. A new CUSIP registration allows the company to validate every real share. My other thought is the following - Let's assume there are 2 billion naked shorts. It's fair to say that the seven market makers combined have enormous influence over the courts, the SEC etc..Say Posner was to make a strong case for manipulation, and won. Would that automatically trigger the 2 billion naked shares to be exposed? If so, what's the mechanism for that to happen? I do know that the court can impose a large fine. Which wouldn't be any worse, but likely much better to split btw the seven,
than to allow for a short squeeze to occur.
So on my second point, if NWBO registers under a new CUSIP, if I understand correctly, the alleged outstanding naked shares would become uncoverable. Would that eventually lead to a reckoning at some point? I guess it depends on how honest the SEC is willing or motivated to do its job.
How does this scenario benefit NWBO:
1. NWBO validates and registers all real shares through the new security.
2. MM'S are no longer trapped and compelled to keep the scheme going for fear of a catastrophic squeeze that could bankrupt them.
3. The court would have less pressure from influence by the MM's, because the case ends up as a large penalty award, without the fear of financial ruin that the MM's are used to living with.
4. NWBO uplists as a new security by merger, without the naked shares weighing the company down and open to institutions to invest with approval in hand and the rest.
Interesting...
Did you see something interesting about this trial on pediatric cancer was run by NCI?
John Glod from NCI was the PI. But the publication doesn't have his name. I haven't never seen a case in which the PI was not listed in the publication.
The correspondence author was Crystal Mackall. Look at her bio.
Dstock well said.
Everyone look what TDD put together, this is the first in a series of posts from TDD, on X
$NWBO
— 🇩🇰 The Danish Dude 🇩🇰 (@FlemmingBruce) April 18, 2024
The Revimmune Connection
1) Northwest Biotherapeutics have a combination patent with DCVax-L and checkpoint inhibitors and Interleukin-7
2) Linda Powers is CEO of Northwest Biotherapeutics
3) Linda Powers owns Toucan Capital
4) Linda Powers is CEO of Advent Bioservices
Sure hope so, CO....
The results would be devastating to the shorts, the pps would rocket up, and I believe a jump back to NASDAQ has been in the works for years, just waiting for the right time.... and then comes the institutional buyers...
I'm of the opinion its all a bit strange, in fairness it was also strange to me when DD did a similar thing in the not too distant past.
managing finances is challenging, i get it. but it all smells very fishy to me.
it is what it is.
GermanCol - You spoke honestly with your heart, and not with your ego, when you decided to share your truth publicly. I didn't see any malice behind your motivation other than to vet your emotions. The mere thought of kicking someone when they're most vulnerable, especially in a public forum is something that's inexplicable and unfortunate in my view. Something I do often when I'm enraged is to open Google Docs, and type up my reply. It prevents me from surrendering my valuable energy any further into an unconstructive circular exchange. If after a little time has past, I still feel driven to stay in the frey, I will cut and paste, otherwise, I either save the doc or delete it entirely.
Everything is about to converge.
Don't fret, GermanCol. This guy has been put on ignore by me and I suspect a few others. He may be long but his foul mouth and insults are too much for some.
ill drop it after this observation, anyone else find it interesting that of ALL the possible posters to dislike my opinion that GermanCol is a short, just so happens to be Whosleftholdingthebag....
did i just call this all out, that easily?
LOL
>>The Company’s lead product, DCVax-L, is currently in a 348-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. The Company’s second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers.
"This video is private"
>>Northwest Bio's CEO presents at SMi's 3rd Cancer Vaccine Conference, detailing progress to-date, as well as the exciting announcement that DCVax-L received the first-ever "Promising Innovative Medicine" (PIM) designation under the UK's "Early Access to Medicines Scheme" (EAMS).
© 2017 Northwest Biotherapeutics, Inc.
4800 Montgomery Lane, Suite 800
Bethesda, MD 20814
he is a wolf in sheeps clothing, is all. No one who actually wants to see the SP go up, goes out of their way to advertise that they sold early...
NWBO at $25 soon. Are you ready?
norisknorewards Easy does it man. Don't know what your problem is with him ,but let up. JJJEEEZZZ
you think anyone here gives a rats F about grammar?
nope, not a chance.
all we care about is why someone as "astute" as yourself, who spends a shit ton of time posting in detail, then goes on explain to the whole group that you're selling, A MONTH TO THREE MONTHS EARLY, BEFORE APPROVAL.
IDIOT!!!!!!!!
SHORT!!!!!!
I'm not going to annoy other posters discussing with somebody that doesn't even know how to speak in what I think is his native language and on the other hand thinks that he knows things that are not true like where I work, how much I sold, etc. Bye, on ignore.
Would be nice....I can only put hope in approval at this juncture....Once approval happens all the other good things could happen in short order....Approval is first!
exactly, i am spot on.
you sold early for a loss because you're horrible at budgeting your finances.
horrible investor, and not a long term long. We're better off removing all the weak hands, like yours.
However, with the above said, i stand by my opinion that you've planned this all along, to try and seem like a long investor, and then pull the rug along with the shorts. Which fund do you work for?
I'm onto you...
what truth hurts, that you sold a month to 3 months early, at a loss?
Ignorant people like you need to insult others when out of arguments. I suggest you to take some English classes and finish school. I can see who is not really smart.
The truth hurts 😂🤣
Nwbo website has been updated. I don’t know the website well enough to have specifics but it looks re organized and the bar chart showing trial status is gone. I’m guessing they are ready to add exciting new information but what could it be LoL
Inquirig,
So many better ways for wealthy folks from this management team to have built more wealth than what Linda, Les and others did to protect this tech and get it to approval stage. Did Les, Alton Boynton, Dr Bosch and all the directors get rich by Cognate being sold?; ). So why didn’t they ditch from being upset about the sale? Why did Shashi Murthy take shares and cash instead of all cash for Flaskworks? The quite obvious answer is that he and the others saw and still see value in the shares but like many investors wanted to take some cash for time and finances invested up to that point of development so he could be working with “house money” so to speak.
You and your “friends” are sounding more and more desperate to make the current silence seem bad when in fact the silence is just creating a golden opportunity for some with your help. Best wishes.
You're the idiot that spent days worth of time on here posting, only to have to sell a quarter early?
If you were smart, you would have planned ahead, and not bought more than you could afford. Instead, you sold whatever you sold at a loss. Well done!
dumbass
Good for you. Think whatever you like.
You wrote:
George - Yep, and "They remain committed.."
Cannonball? Goliath? Once approval, I expect them to concentrate on next approval, getting treatment to those who need it, getting the word out, partnerships, and sales. This isn't art of war. Get approval, then concentrate on next approval, naked shorts and shortsellers should be in rear view window. We are weeks away from approval. I hope not to hear anymore delays such as they need proofreaders to go over FDA submission. This is time to ramp up the machinery, not fooling around with shortsellers. I dont want a chessplayer right now, I want someone who gets this to market.
Probably that NWBO shareholders can fund yet another company of which they will see no benefit. Just like Cognate and Advent. Call it the LP Sucker Trifecta
It is pretty clear. Which BP knows DCVax-L better than BMS? Would BMS do some due diligence before striking the collaboration deal with NWBO by going through some first hand data in NWBO's safe? Absolutely. Keep in mind. BMS has close collaboration with professor I. Melero who did a trial using his version of DCs combined with Poly-ICLC. But he didn't make any breakthrough. But he did publish a paper with Salazar.
It would an insult on my character if people of your kind like me.
BTW, is this relevant?
This is the trial on prostate cancer using the combination of RevImmune's CYT107 with Provenge.
— d_stock (@d_stock07734) April 24, 2024
Conclusions: Treatment with rhIL-7 led to a significant expansion of CD4+ and CD8+ T cells, and CD56bright natural killer (NK) cells compared with observation after treatment with… pic.twitter.com/PBa14ghHP8
Hmmm BMS calls cell therapy a franchise.
From my interview with $BMY CEO, where I asked about cell therapy layoffs:
— Matthew Herper (@matthewherper) April 25, 2024
"Cell therapy is just one of those areas that we’ve been looking at to make important prioritization decisions. But we are still absolutely committed to cell therapy as a franchise because we think it has…
You are calling someone dumb? Neither the delusional longs nor the shills on this board like you and you don't realize it.
This must be relevant.
This is the trial on pediatric solid tumors (Ewing's sarcoma, rhabdomyosarcoma, and neuroblastoma). IMO, the combination is RevImmune's CYT107 and DCVax-L. The results are truly amazing given the following statistics:
— d_stock (@d_stock07734) April 24, 2024
The 5-year overall survival (OS) rates in paediatric patients… pic.twitter.com/cVPxpd6PRs
While also at this time, Northwest Therapeutics changed its legal structure from LTD to INC filed on January 24th of this year. These are deliberate strategic actions.
Not denying it, but where is PR to let shareholders of NWBO know or potential shareholders? At least they have a good website, which show combo trials. How does the market know the relationship between the 2 companys?
Followers
|
1624
|
Posters
|
|
Posts (Today)
|
184
|
Posts (Total)
|
689378
|
Created
|
02/02/05
|
Type
|
Free
|
Moderators XenaLives sentiment_stocks CaptainObvious Poor Man - Doc logic JerryCampbell |
“Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning.”
~ Winston Churchill
Stylized Dendritic Cell featured on NWBO board since 2015
- Dr. Linda Liau, PhD, MBA, Professor and Chair, Department of Neurosurgery, David Geffen School of Medicine at UCLA
Clinical Trials
DCVax®-L to Treat Newly Diagnosed GBM Brain Cancer (NCT00045968) - Phase III (Double Blind)
UK (MHRA): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
DE (Germany - PEI): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
Expanded Access Protocol for GBM Patients with Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 (NCT02146066) (Expanded Access)
Safety and Efficacy Study of DCVax-Direct in Solid Tumors (NCT01882946) - Phase I/Phase II (Open Label)
UK Clinical Trials - Study of a Drug (DCVax®-L) to Treat Newly Diagnosed GBM Brain Cancer
EU Clinical Trials for DCVax-L - Phase III
Dendritic Cell Vaccine for Patients with Brain Tumors (NCT01204684) - Phase II - at UCLA - Randomized (Open Label) testing DCVaccine with Resiquimod and DC Vaccination with Adjuvant polyICLC
Pembrolizumab and a Vaccine (ATL-DC) for the treatment of Surgically Accessible Recurrent Glioblastoma - Phase 1 (NCT04201873)
Dendritic Cell-Autologous Lung Tumor Vaccine (DCVax-L) and Nivolumab in Treating Patients with Recurrent Glioblastoma - Phase 2 (NCT03014804)
Dendritic Cell Therapy for Brain Metastases From Breast or Lung Cancer (NCT0368765) - Phase 1 - Collaborator: Mayo Clinic
Announcement of DCVax-L and Anti-PD-1 Monoclonal Antibody (Pembrolizumab) for Patients with Liver Metastases of Primary Colorectal Carcinoma Phase 2 Trial - November 17, 2016 - University Medical Center (UMC) of the Johannes Gutenberg University of Mainz
Cognate Bioservices - Owned by Charles River Labs
Website
Company Contact Info
Investor Relations:
Les Goldman (Company) (202) 841-7909 lgoldman@nwbio.com
Sign up for Northwest email list here (hit the subscribe to email list button in the lower right)
Company Headquarters
4800 Montgomery Lane, Suite 800, Bethesda, MD 20814 (240) 497-9024
NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio’s proprietary manufacturing technology enables them to produce its personalized vaccine in an efficient, cost-effective manner. NW Bio has a broad platform technology for DCVax dendritic cell-based vaccines.
Their lead product, DCVax-L, is currently in a 331-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. This trial is currently underway at 69 locations thoughout the United States, Germany and the United Kingdom. NW Bio has also conducted a Phase I/II trial with DCVax-L for late stage ovarian cancer together with the University of Pennsylvania.
Their second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers, with trials currently being conducted at both MD Anderson Cancer Center in Texas, as well as Orlando Health in Florida.
They previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.
DCVAX Survival Stories & Testimonials
Alice - Metastic Merkel Cell patient from Florida - ASCO 2018
Brad Silver - GBM patient from Huntington Beach, California - ASCO 2018
Sarah Rigby - GBM patient from Hong Kong - ASCO 2018
Kristyn Power - daughter of GBM patient from Canada - ASCO 2018
Kat Charles - GBM patients from UK - ASCO 2018 - as related by her husband Jason (Kat's Cure)
Prospective patients may contact NW Bio at patients@nwbio.com
UCLA Jamil Newirth DCVax-Patient Video - 2015
Allan Butler Video - National Geographic Vice President - DCVax-Direct patient from Phase 1 Trial with Pancreatic Cancer
NWBO - Patients Sunday Dennis and Jami Newirth - Enrolled at UCLA - Vimeo, Uploaded approx. May 2015
NWBO - Vaccine Helps Keep Brain Cancer Patient Alive (Jennifer Sugioka) - NBC Channel 4, Southern California, February 24, 2015
NWBO - National Geographic's Allan Butler Stage IV Pancreatic Patient using DCVax-Direct at MD Anderson
NWBO GBM Brain Cancer Survival Story of Mark Pace
Presentations
UCLA Agreements
Prostrate
DCVax-Phase II
DCVax-Booster
Upcoming Events
Videos
Linda M. Liau, MD, PhD, MBA - April 24, 2019 at University of Washington, Neurosciences Institute
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |